Trial · NCT03181503
Adverse events48
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 48
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Placebo | 4 | 36 | |
| other | Nasopharyngitis | Infections and infestations | Nemolizumab 0.5 mg/kg | 5 | 34 | |
| other | Conjunctivitis | Infections and infestations | Placebo | 2 | 36 | |
| other | Conjunctivitis | Infections and infestations | Nemolizumab 0.5 mg/kg | 3 | 34 | |
| other | Bronchitis | Infections and infestations | Placebo | 0 | 36 | |
| other | Bronchitis | Infections and infestations | Nemolizumab 0.5 mg/kg | 2 | 34 | |
| other | Cystitis | Infections and infestations | Placebo | 2 | 36 | |
| other | Cystitis | Infections and infestations | Nemolizumab 0.5 mg/kg | 0 | 34 | |
| other | Postoperative Wound Infection | Infections and infestations | Placebo | 2 | 36 | |
| other | Postoperative Wound Infection | Infections and infestations | Nemolizumab 0.5 mg/kg | 0 | 34 | |
| other | Neurodermatitis | Skin and subcutaneous tissue disorders | Placebo | 5 | 36 | |
| other | Neurodermatitis | Skin and subcutaneous tissue disorders | Nemolizumab 0.5 mg/kg | 2 | 34 | |
| other | Dermatitis Atopic | Skin and subcutaneous tissue disorders | Placebo | 0 | 36 | |
| other | Dermatitis Atopic | Skin and subcutaneous tissue disorders | Nemolizumab 0.5 mg/kg | 3 | 34 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Placebo | 2 | 36 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Nemolizumab 0.5 mg/kg | 0 | 34 | |
| other | Dermatitis Contact | Skin and subcutaneous tissue disorders | Placebo | 0 | 36 | |
| other | Dermatitis Contact | Skin and subcutaneous tissue disorders | Nemolizumab 0.5 mg/kg | 2 | 34 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Placebo | 2 | 36 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Nemolizumab 0.5 mg/kg | 0 | 34 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/events